Your technology is TRL 9. So why is nobody buying it?

The pilot worked. The engineers are quietly pleased. The data holds up under scrutiny. The deck has three charts with the arrows pointing the right way. The room nods along. And then the senior person on the other side of the table smiles and says:

“Very interesting. Please keep us updated.”

That’s it. No objection. No competitor named. No price argument. Just a polite door closing so softly you don’t hear the latch. Founders spend months trying to reopen it, usually by adding more of the thing that was never the problem.

Because the problem here is almost never the technology. The technology is fine. The problem is that you’re measuring readiness on the wrong scale.

Two scales, and everyone only watches one

Engineers have a clean way to talk about how proven a technology is: the Technology Readiness Level. NASA built it, it runs 1 to 9, and TRL 9 means the system has run successfully in its real operating environment. Proven. Finished. Real.

Ready for what, though? That’s where the expensive confusion sets in — because TRL says precisely nothing about whether a market can buy the thing.

There is a second scale, built for exactly this question, and far fewer people use it. The Commercial Readiness Index, developed by the Australian Renewable Energy Agency in 2014 for renewable energy sectors, runs 1 to 6 and measures everything TRL ignores: the regulatory pathway, the financial case, the supply chain, stakeholder acceptance, whether anyone can actually procure it.

Here’s the uncomfortable part. You can be TRL 9 and CRI 1 at the same time. Technology complete, commercial architecture not yet started. In clean tech, that combination isn’t the exception. It’s the default.

Why the pilot fools everyone

A pilot is designed to answer an engineering question: does it work? And when it does, everyone in the building treats that as the finish line.

But the pilot usually sits outside the buyer’s real procurement process. It’s paid from an innovation budget. It’s championed by one curious engineer. Internally it’s framed as a low-risk experiment — which is exactly why everyone could say yes so easily. Nobody was really committing.

The purchase decision happens later, in a different room, with people who were never at your pilot: operations, procurement, finance, legal, the person who owns the P&L. They don’t evaluate novelty. They evaluate risk. And they ask questions your beautiful pilot data can’t answer:

Has this worked somewhere that looks like us? Who verified it besides the vendor? Can I call an operator who’s lived with it for two years? What happens the day it fails at 3 a.m.? Who services it in year five? What budget line does this even come out of?

A successful pilot moves your TRL. It barely touches your CRI. That gap is where the money quietly disappears.

Why investors should care more than they usually do

A high TRL feels like reduced risk, and it is — it kills technical uncertainty. But it leaves the expensive risks fully intact: procurement, reference credibility, the survival of a small supplier through an 18-month institutional sales cycle, whether a project can be financed, insured, and warranted at all.

A pipeline of ten active pilots looks like traction on a board slide. If none of them has a path to a purchase order, it isn’t traction — it’s ten expensive experiments wearing a traction costume. A company with a mature product and weak commercial readiness can burn capital astonishingly fast, funding more pilots and more certifications while the market waits for something completely different: references, buyer-side evidence, delivery capability, trust.

The spreadsheet files this under “go-to-market execution risk.” The buyer files it under: “We’ll wait until someone braver goes first.”

Why hiring more salespeople usually makes it worse

The reflex, when conversion stalls, is to add sales headcount. Sometimes that’s right. Often it’s premature, because more sales capacity cannot manufacture the thing that’s actually missing.

Salespeople can’t create a reference in the buyer’s exact segment. They can’t invent a budget line inside a utility. They can’t make a vendor-funded pilot read as independent evidence. They can’t repair a commercial model that leaves the buyer holding all the operational, regulatory, and counterparty risk. Point more sales effort at a CRI problem and you get the same “keep us updated,” just more expensively.

The better question isn’t how do we sell more? It’s sharper than that:

Which single commercial condition is stopping a qualified, willing buyer from moving to procurement?

A rule worth taping to the wall

From roughly TRL 5 onward, every technical investment should carry a commercial companion question. If your team can’t answer it cleanly, you may be polishing the technology while widening the gap:

• Pilot → What procurement-grade evidence will this actually produce?
• Certification → Which specific buyer decision does it unlock?
• Reference site → Is this host a credible peer for the next buyer?
• Product development → What buyer risk does this reduce?
• New market → Do we have a local route to trust, delivery, and service?

The strongest clean-tech companies I work with don’t wait for technical completion before building commercial readiness. They score TRL and CRI separately, watch the spread, and when the technology is miles ahead of the market — the usual case — they spend the next dollar on the commercial architecture, not the lab.

Because a technology doesn’t become commercial the day the lab says it works.

It becomes commercial the day a buyer can responsibly say yes.

---

Illustrative composite based on documented commercialization patterns; not a specific company.